Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs.

AIMS To quantify and compare the incidence of ventricular arrhythniias associated with the use of five nonsedating antihistamines: acrivastine, astemizole, cetirizine, loratadine and terfenadine. The effects of age, sex, dose, duration of treatment, and the interaction with P450 inhibitor drugs were also examined. METHODS We carried out a cohort study with a nested case-control analysis using the UK-based General Practice Research database (GPRD). The study cohort included persons aged less than 80 years old who received their first prescription for any of the five study drugs between January 1, 1992 and September 30, 1996. We estimated relative risks and 95% confidence intervals of idiopathic ventricular arrhythmias with current use of antihistamines as compared with non use. RESULTS The study cohort included 197425 persons who received 513012 prescriptions. Over the study period 18 valid cases of idiopathic ventricular arrhythmias were detected. Nine occurred during the current use of any antihistamine, resulting in a crude incidence of 1.9 per 10000 person-years (95%CI: 1.0-3.6) and a relative risk of 4.2 (95%CI: 1.5-11.8) as compared with non use. Astemizole presented the highest relative risk (RR= 19.0; 95%CI: 4.8-76.0) of all study drugs, while terfenadine (RR=2.1; 95%CI:0.5-8.5) was in the range of other nonsedating antihistamines. Older age was associated with a greater risk of ventricular arrhythmias (RR=7.4; 95%CI: 2.6-21.4) and seemed to increase the effect of antihistamines (RR=6.4; 95%CI: 1.7-24.8). The proportions of high dose terfenadine and the concomitant use with P450 inhibitors among current users of terfenadine were 2.7% and 3.4%, respectively over the study period with no single case of ventricular arrhythmias occurring in the presence of these two risk factors. CONCLUSIONS The use of nonsedating antihistamines increases the risk of ventricular arrhythmias by a factor of four in the general population. Yet, the absolute effect is quite low requiring 57000 prescriptions, or 5300 person-years of use for one case to occur. The risk associated with terfenadine was no different from that with other nonsedating antihistamines.

[1]  A. Rankin.  Non-sedating antihistamines and cardiac arrhythmia , 1997, The Lancet.

[2]  H Jick,et al.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.

[3]  C. Pratt,et al.  Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. , 1994, The American journal of cardiology.

[4]  M. Lindquist,et al.  Risks of non-sedating antihistamines , 1997, The Lancet.

[5]  W. Amery,et al.  Risk of selected serious cardiac events among new users of antihistamines. , 1995, Clinical therapeutics.

[6]  H. B. Pepinsky,et al.  Observation and inference. , 1954 .

[7]  F. Guengerich,et al.  Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[8]  R. Platt,et al.  Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. , 1995, Annals of epidemiology.

[9]  J. Tamargo,et al.  Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. , 1997, Cardiovascular research.

[10]  Y. Horsmans,et al.  Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines , 1995, Clinical pharmacokinetics.

[11]  T M Craft,et al.  Torsade de pointes after astemizole overdose. , 1986, British medical journal.

[12]  A. Stanners,et al.  Torsades de pointes complicating treatment with terfenadine. , 1991, BMJ.

[13]  F. Simons,et al.  H1-Receptor Antagonists , 1994, Drug safety.

[14]  R. Woosley,et al.  Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.

[15]  B McNutt,et al.  Torsades de pointes occurring in association with terfenadine use. , 1991, JAMA.

[16]  R. Heel,et al.  Terfenadine , 2012, Drugs.

[17]  A. E. Lacerda,et al.  Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. , 1997, Molecular pharmacology.

[18]  S. Gutthann,et al.  Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.

[19]  A. Pelech,et al.  ASTEMIZOLE-INDUCED TORSADE DE POINTES , 1988, The Lancet.